Insider Selling: Pharvaris (NASDAQ:PHVS) President Sells $601,950.00 in Stock

by · The Markets Daily

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) President Peng Lu sold 15,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $40.13, for a total value of $601,950.00. Following the transaction, the president owned 65,179 shares in the company, valued at approximately $2,615,633.27. This trade represents a 18.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peng Lu also recently made the following trade(s):

  • On Tuesday, September 8th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $40.68, for a total value of $610,200.00.
  • On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The stock was sold at an average price of $34.00, for a total value of $10,200.00.

Pharvaris Stock Performance

Shares of NASDAQ PHVS opened at $38.00 on Friday. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -12.46 and a beta of -2.33. The business’s 50-day simple moving average is $35.35 and its 200-day simple moving average is $31.69. Pharvaris N.V. has a 52 week low of $20.65 and a 52 week high of $43.25.

Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently modified their holdings of the stock. Engineers Gate Manager LP bought a new position in Pharvaris during the second quarter worth $1,143,000. Amundi increased its holdings in shares of Pharvaris by 61.4% during the 2nd quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after purchasing an additional 18,992 shares during the period. Moore Capital Management LP bought a new position in shares of Pharvaris during the 2nd quarter worth about $1,522,000. Alyeska Investment Group L.P. raised its position in shares of Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after buying an additional 281,829 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares during the period.

Analyst Ratings Changes

A number of analysts have recently weighed in on PHVS shares. Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. UBS Group set a $79.00 target price on shares of Pharvaris in a research note on Wednesday, September 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Pharvaris in a report on Monday. Finally, Royal Bank Of Canada boosted their target price on shares of Pharvaris from $52.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and an average price target of $59.87.

View Our Latest Research Report on PHVS

About Pharvaris

(Get Free Report)

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

Further Reading